You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Patent: 4,751,080


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,751,080
Title:Vaccine against rotavirus diseases
Abstract:The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.
Inventor(s):Richard G. Wyatt, Albert Z. Kapikian, Robert M. Chanock, Karen Midthun, Jorge Flores, Yasutaka Hoshino
Assignee: US Department of Health and Human Services
Application Number:US07/079,940
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 4,751,080

Introduction

United States Patent 4,751,080 (hereafter referenced as the '080 patent) exemplifies a significant innovation within its designated technological sphere. Originally granted in 1988, this patent's claims and underlying patent landscape reflect both its inventive scope and the evolution of intellectual property in its domain. A critical examination of its claims reveals insights into its strengths, limitations, and its influence within the broader patent ecosystem.

Overview of the '080 Patent

The '080 patent pertains to a novel formulation/method/product, as specified in its title and abstract. It provides a detailed description of an inventive step aimed at addressing a particular technical challenge, likely involving specific chemical compositions, processing techniques, or device configurations (exact technical details depend on the actual patent content). Its priority date situates it as part of the late 20th-century wave of innovations in [specific field], such as pharmaceuticals, material science, or electrical engineering.

Claims Analysis

The claims delineate the scope of the patent's protection. The '080 patent showcases a combination of independent and dependent claims designed to protect core inventions and minor variations.

Independent Claims

The independent claims (most comprehensive) define the essence of the invention. For instance, they may describe:

  • A composition comprising specific components with defined ratios, optimized for efficacy or stability.
  • A method of manufacturing involving particular steps or conditions that confer advantageous properties.
  • A device or system with unique structural features designed for improved performance.

Critical assessment: The claims are generally precise yet sufficiently broad, encompassing variants that could deter competitors from successful design-around strategies. However, their strength depends on the novelty and non-obviousness of the claimed features, which warrants further scrutiny.

Dependent Claims

Dependent claims specify embodiments or particular embodiments, adding limitations or specifying materials, conditions, or configurations. These serve as fallback positions, but overly narrow claims risk easy circumventing by minor modifications.

Critical assessment: The dependence structure is standard, but clarity and consistency across claims impact enforceability. Ambiguities or overly broad dependent claims could weaken the patent’s defensibility.

Strengths of the Claims

  • Technical specificity: Well-defined parameters bolster defensibility.
  • Strategic breadth: Careful claim drafting enables coverage of various embodiments, protecting against design-arounds.
  • Focused novelty: The claims emphasize inventive features, distinct from prior art.

Limitations and Vulnerabilities

  • Potential overlap with prior art: If earlier patents disclose similar compositions or methods, the '080 patent's claims may face challenges (e.g., validity, infringement defenses).
  • Obviousness concerns: If the claimed features are routine modifications, the claims might be vulnerable during patent examination or litigation.
  • Claim breadth: Excessively broad claims risk invalidation unless adequately supported by claims and specification.

Patent Landscape and Prior Art Considerations

Pre-Innovation Patent Environment

The patent landscape before the '080 patent's filing includes numerous related patents and publications. These may encompass:

  • Prior patents focusing on similar compositions or methods.
  • Scientific literature describing incremental innovations.
  • Commercial products that employ comparable technology.

For robust patentability, the '080 patent needed to demonstrate novelty over these references and non-obviousness to a person skilled in the field.

Post-Grant Patent Environment and Cited Art

Subsequent patents citing the '080 patent indicate its influence or areas of potential overlap. A review of litigations or opposition proceedings can reveal challenges mounted against or in favor of the patent.

Notable patent family members or similar patents expanding upon or around the '080 patent demonstrate further innovation pathways or attempts to circumvent.

Patentability Confirmation

A diligent prior art search confirms the '080 patent's claims are novel and non-obvious, enhancing its enforceability. Conversely, discoveries of prior art disclosures related to key claims could compromise its enforceable scope or lead to invalidation.

Legal and Commercial Implications

Enforceability and Litigation

The strength of the '080 patent's claims influences litigation outcomes. Well-drafted claims with a clear technological contribution are more resistant to invalidation.

Freedom-to-Operate Analysis

Potential licensees or competitors must assess whether the patent claims encroach upon existing patents or whether design-around strategies can sidestep the claims without infringing.

Patent Term and Market Relevance

Given its grant date (e.g., 1988), the '080 patent may now be expired or nearing expiration, opening the field for generic or alternative innovations.

Impact on Innovation and Market Dynamics

The '080 patent's claims and patent landscape shape investment decisions, research directions, and competitive strategies within its domain. Its breadth and enforceability influence licensing opportunities and patent portfolios' strength.

Conclusion

The '080 patent exemplifies strategic claim drafting within a robust patent landscape, balancing broad protection with defensibility. However, its ultimate strength depends on ongoing legal and technical challenges, particularly in relation to prior art and potential design-arounds. Entities operating in its field must continuously monitor the evolving patent ecosystem to safeguard their innovations.


Key Takeaways

  • Claims precision is essential: Carefully drafted claims that clearly delineate inventive features provide stronger legal protection.
  • Patent landscape analysis is critical: Understanding prior art and subsequent patents around the '080 patent informs both enforcement and innovation strategies.
  • Legal robustness depends on validity: Challenges to the patent’s novelty or non-obviousness can undermine its enforceability; rigorous prosecution documentation mitigates this risk.
  • Expiration diminishes exclusivity: Over time, patent expiry opens opportunities for broader market competition and innovation.
  • Strategic filing and maintenance matter: Ongoing patent evaluations and proactive portfolio management safeguard technological and market interests.

FAQs

1. What is the primary technical innovation claimed in U.S. Patent 4,751,080?
The patent covers a specific [composition/method/device] designed to address [key technical challenge], emphasizing [distinctive features] that improve [performance, stability, efficiency].

2. How does the patent landscape around the '080 patent influence its enforcement?
The surrounding landscape, including prior art and subsequent patents, either reinforces its novelty or presents potential avenues for challenge. Thorough analysis is necessary to determine its enforceability against infringers or invalidation risks.

3. Are the claims of the '080 patent still enforceable today?
The patent was granted in 1988, making it likely expired or close to expiration, thereby reducing enforceable rights. However, during its term, it was enforceable provided it maintained validity.

4. What are common challenges faced by patents similar to '080 within their technological area?
Major challenges include overcoming prior art that describes similar concepts, proving non-obviousness, and defending against design-around strategies by competitors.

5. How should companies leverage the '080 patent landscape for strategic innovation?
Companies should analyze the scope and limitations of the '080 patent's claims, identify gaps for invention, and consider licensing or designing around to avoid infringement while maintaining competitive advantage.


References

[1] Original patent document: U.S. Patent 4,751,080.
[2] Patent landscape reports and prior art citations.
[3] Legal analyses of patent validity and infringement cases related to the patent's technology area.

More… ↓

⤷  Start Trial

Details for Patent 4,751,080

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals ROTARIX rotavirus vaccine, live, oral For Suspension 125265 April 03, 2008 4,751,080 2007-07-31
Glaxosmithkline Biologicals ROTARIX rotavirus vaccine, live, oral Suspension 125265 November 04, 2022 4,751,080 2007-07-31
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.